Ikonisys: the 2023 Annual Report is now available

Ikonisys: the 2023 Annual Report is now available

Paris, France - July 8, 2024 - 5.45 pm CEST - Ikonisys SA (Euronext Growth Paris: ALIKO), a leading company in early and accurate cancer diagnosis through cutting-edge and fully automated solutions for medical analysis laboratories, hereby announces that its 2023 Annual Financial Report, for the year ended December 31, 2023, is now available and was filed with the Autorité des Marchés Financiers (AMF).

The document is available on the Company's investor website: http://www.ikonisys-finance.com (in the Documentation > Financial report section).

About Ikonisys

Ikonisys SA is a cell-based diagnostics company based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialized in the early and accurate detection of cancer. The company develops, produces and markets the proprietary Ikoniscope20® and Ikoniscope20max® platforms, fully-automated solutions designed to deliver accurate and reliable detection and analysis of rare and very rare cells. Ikonisys has received FDA clearance for several automated diagnostic applications, which are also marketed in Europe under CE certification. Through its breakthrough fluorescence microscopy platform, the company continues to develop a stream of new tests, including liquid biopsy tests based on Circulating Tumor Cells (CTC).

For further information, please go to http://www.ikonisys-finance.com

Disclaimer

This press release contains forward-looking statements about the Company's prospects and development. These statements are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as "believe", "aim to", "expect", "intend", "estimate", "believe", "should", "could", "would" or "will" or, where appropriate, the negative of these terms or any other similar variants or expressions. This information is not historical data and should not be construed as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic, financial, competitive and regulatory environment. This information contains data relating to the Company's intentions, estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of the Company. The forward-looking information contained in this press release is made only as of the date of this press release. The Company does not undertake to update any forward-looking information contained in this press release, except as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking information constitutes a guarantee of actual results.

previous

Ikonisys reports its Full-Year Financial Results for 2023 and provides an update on its latest developments

next

Ikonisys announces that Hospitex International signed supply contracts in Italy marking growth potential for the Group